Focused On-demand Library for BOS complex subunit TMEM147

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We use our state-of-the-art dedicated workflow for designing focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q9BVK8

UPID:

TM147_HUMAN

Alternative names:

Protein NIFIE 14; Transmembrane protein 147

Alternative UPACC:

Q9BVK8; A8MWW0; O75790

Background:

BOS complex subunit TMEM147, also known as Protein NIFIE 14 and Transmembrane protein 147, plays a crucial role in the insertion of multi-pass membrane proteins into lipid bilayers. It functions as part of the multi-pass translocon (MPT) complex, facilitating the insertion process post the SEC61 complex's initial engagement. Additionally, TMEM147 negatively regulates CHRM3 function and calcium mobilization, impacting RPS6KA1/p90RSK activity and influencing LBR localization to the nucleus inner membrane.

Therapeutic significance:

Understanding the role of BOS complex subunit TMEM147 could open doors to potential therapeutic strategies, particularly in addressing Neurodevelopmental disorder with facial dysmorphism, absent language, and pseudo-Pelger-Huet anomaly, a condition directly linked to variants affecting this gene.